ALPTEKİN, K. Et Al. 2019. Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients. 32nd ECNP , (Kopenhag, Denmark).

ALPTEKİN, K., ANIL YAĞCIOĞLU, A. E., EKER, S. S., Yıldız, M., Kaymak Ulusoy, S., TAMAM, L., ... YAZICI, M. K.(2019). Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients . 32nd ECNP, Kopenhag, Denmark

ALPTEKİN, KÖKSAL Et Al. "Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients," 32nd ECNP, Kopenhag, Denmark, 2019

ALPTEKİN, KÖKSAL Et Al. "Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients." 32nd ECNP , Kopenhag, Denmark, 2019

ALPTEKİN, K. Et Al. (2019) . "Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients." 32nd ECNP , Kopenhag, Denmark.

@conferencepaper{conferencepaper, author={KÖKSAL ALPTEKİN Et Al. }, title={Arilai: a naturalistic open-label study of aripiprazole long acting injectable efficacy on functioning and quality of life in schizophrenia patients}, congress name={32nd ECNP}, city={Kopenhag}, country={Denmark}, year={2019}}